Brand Name
Xermelo
Generic Name
Telotristat
View Brand Information FDA approval date: March 01, 2017
Classification: Tryptophan Hydroxylase Inhibitor
Form: Tablet
What is Xermelo (Telotristat)?
Xermelo is indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults inadequately controlled by SSA therapy. Xermelo is a tryptophan hydroxylase inhibitor indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults inadequately controlled by SSA therapy.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment